PL4426298T3 - Nowe kombinacje terapeutyczne zawierające pirfenidon i inhibitor pde4 do leczenia postępujących włókniejących śródmiąższowych chorób płuc - Google Patents

Nowe kombinacje terapeutyczne zawierające pirfenidon i inhibitor pde4 do leczenia postępujących włókniejących śródmiąższowych chorób płuc

Info

Publication number
PL4426298T3
PL4426298T3 PL22839143.9T PL22839143T PL4426298T3 PL 4426298 T3 PL4426298 T3 PL 4426298T3 PL 22839143 T PL22839143 T PL 22839143T PL 4426298 T3 PL4426298 T3 PL 4426298T3
Authority
PL
Poland
Prior art keywords
pirfenidone
pde4
inhibitor
treatment
new therapeutic
Prior art date
Application number
PL22839143.9T
Other languages
English (en)
Inventor
Christian Hesslinger
Verena BAUER
Sebastian Martin BOSSERT
Susan KOBER
Yi Liu
Peter Nickolaus
Maria Sarno
Florian Voss
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL4426298T3 publication Critical patent/PL4426298T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL22839143.9T 2021-12-09 2022-12-08 Nowe kombinacje terapeutyczne zawierające pirfenidon i inhibitor pde4 do leczenia postępujących włókniejących śródmiąższowych chorób płuc PL4426298T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163287641P 2021-12-09 2021-12-09
EP21218207 2021-12-29
EP22177757 2022-06-08
PCT/EP2022/084972 WO2023104961A1 (en) 2021-12-09 2022-12-08 New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases

Publications (1)

Publication Number Publication Date
PL4426298T3 true PL4426298T3 (pl) 2026-07-20

Family

ID=84887580

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22839143.9T PL4426298T3 (pl) 2021-12-09 2022-12-08 Nowe kombinacje terapeutyczne zawierające pirfenidon i inhibitor pde4 do leczenia postępujących włókniejących śródmiąższowych chorób płuc

Country Status (19)

Country Link
US (2) US20230190754A1 (pl)
EP (3) EP4426298B1 (pl)
JP (2) JP2024541514A (pl)
KR (2) KR20260004529A (pl)
AU (3) AU2022404695B2 (pl)
CA (1) CA3236757A1 (pl)
CL (2) CL2024001530A1 (pl)
DK (1) DK4426298T3 (pl)
ES (1) ES3066432T3 (pl)
FI (1) FI4426298T3 (pl)
HR (1) HRP20260398T1 (pl)
IL (1) IL312742A (pl)
LT (1) LT4426298T (pl)
MX (2) MX2024006271A (pl)
PL (1) PL4426298T3 (pl)
RS (1) RS67899B1 (pl)
SI (1) SI4426298T1 (pl)
TW (2) TW202615042A (pl)
WO (1) WO2023104961A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025528779A (ja) * 2022-08-09 2025-09-02 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Ｐｄｅ４ｂ阻害剤及びその用途
CN121127461A (zh) * 2023-04-03 2025-12-12 上海壹迪生物技术有限公司 二氢噻吩并嘧啶类化合物、其制备方法和应用
CN116925099B (zh) * 2023-07-21 2025-06-03 厦门大学 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物
CN117717554A (zh) * 2023-12-19 2024-03-19 中国医学科学院基础医学研究所 吡非尼酮联合尼达尼布在制备治疗尘肺病的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057618A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057645A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057594A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
HRP20090395T1 (hr) 2006-04-19 2009-08-31 Boehringer Ingelheim International Gmbh Dihidrotienpirimidini za liječenje upalnih bolesti
RU2500681C2 (ru) 2007-10-19 2013-12-10 Берингер Ингельхайм Интернациональ Гмбх Замещенные гетероциклом пиперазинодигидротиенопиримидины
SI2610258T1 (sl) 2007-10-19 2014-12-31 Boehringer Ingelheim International Gmbh Substituirani piperidino-dihidrotienopirimidini
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
LT3700529T (lt) * 2017-10-23 2025-10-10 Naujas veikliųjų medžiagų derinys, skirtas progresuojančių fibrozinių intersticinių plaučių ligų (pf-ild) gydymui
CN115361950A (zh) * 2020-04-01 2022-11-18 勃林格殷格翰国际有限公司 生物标记物在治疗纤维化病症中的用途

Also Published As

Publication number Publication date
SI4426298T1 (sl) 2026-06-30
CL2024001530A1 (es) 2024-11-22
TW202615042A (zh) 2026-04-16
CA3236757A1 (en) 2023-06-15
KR20240116816A (ko) 2024-07-30
MX2024010637A (es) 2024-09-06
EP4494701A3 (en) 2025-04-02
HRP20260398T1 (hr) 2026-05-08
AU2025271047A1 (en) 2025-12-11
MX2024006271A (es) 2024-06-11
US20250017934A1 (en) 2025-01-16
DK4426298T3 (da) 2026-03-30
US20230190754A1 (en) 2023-06-22
IL312742A (en) 2024-07-01
WO2023104961A1 (en) 2023-06-15
EP4426298A1 (en) 2024-09-11
RS67899B1 (sr) 2026-04-30
EP4426298B1 (en) 2026-02-11
EP4520394A3 (en) 2025-04-02
TW202342050A (zh) 2023-11-01
FI4426298T3 (fi) 2026-03-20
AU2025271046A1 (en) 2025-12-11
KR20260004529A (ko) 2026-01-08
CL2024003601A1 (es) 2025-03-21
ES3066432T3 (en) 2026-05-13
EP4520394A2 (en) 2025-03-12
AU2022404695B2 (en) 2025-08-28
EP4494701A2 (en) 2025-01-22
JP2026116968A (ja) 2026-07-14
AU2022404695A1 (en) 2024-05-02
LT4426298T (lt) 2026-04-10
JP2024541514A (ja) 2024-11-08